FDA.reportPublic FDA data

miltefosine 50 MG [Impavido]

RxCUI
1495066
RxNorm name
miltefosine 50 MG [Impavido]
Term type
SBDC
Status
Active
Updated
2026-10-04 02:02:37

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
052014
Active start
052014
Multiple ingredient
NO
Branded
YES

Ingredients And Strength#

Ingredient, Strength, Base table
IngredientStrengthBaseBasis of strength
50 MG / 1 EACHmiltefosine

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
miltefosine1494066

Source Vocabulary Codes#

Code type, Values, Count table
Code typeValuesCountCategory
PRESCRIBABLEY1ATTRIBUTES
RXNAV_STRmiltefosine 50 MG [Impavido]1NAMES
RxNorm Namemiltefosine 50 MG [Impavido]1NAMES
TTYSBDC1ATTRIBUTES
RxCUI14950661CODES

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 0 matching rows.

No records found.

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCP01CXOther agents against leishmaniasis and trypanosomiasisATC1-4miltefosine
FDASPLN0000190851AntileishmanialEPChas_epcmiltefosine
MEDRTD010767PhosphorylcholineCHEMhas_ingredientmiltefosine
MEDRTD004342Drug HypersensitivityDISEASEci_withmiltefosine
MEDRTD016773Leishmaniasis, CutaneousDISEASEmay_treatmiltefosine
MEDRTD007898Leishmaniasis, VisceralDISEASEmay_treatmiltefosine
MEDRTD011247PregnancyDISEASEci_withmiltefosine
MEDRTD016111Sjogren-Larsson SyndromeDISEASEci_withmiltefosine
MEDRTN0000181812Lysophospholipid Receptor InteractionsMOAhas_moamiltefosine

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESGENERAL_CARDINALITYSINGLE
ATTRIBUTESRXNAV_HUMAN_DRUGUS